In the Middle East, various pay-to-prescribe schemes were used to induce healthcare providers to increase their prescriptions of Sanofi products. Charles Cain, FCPA unit chief at US SEC ...

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved ... approval of Merilog to Sanofi (SNY)-Aventis U.S ...

Products that do not qualify for NAS status are considered to fall under the existing period of exclusivity of the previously authorised product, and for alglucosidase alfa. Sanofi said it would ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Regeneron argues that it can’t be certain the deals don’t unfairly advantage other Sanofi products at Dupixent’s expense. Dupixent is a critical drug for both Regeneron and Sanofi ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Kuehne+Nagel supports Sanofi in multiple countries worldwide, including Hungary, the UK, and the UAE, by providing customised ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.

Sanofi's Sarclisa (isatuximab ... recently gained approval from China’s National Medical Products Administration, in particular for the Sarclisa-VRd combo for treating NDMM individuals who ...